RecruitingEarly Phase 1NCT05700617

Cardiac Power Output in Cardiogenic Shock Patients

Myocardial Reserve in Advanced Heart Failure Patients


Sponsor

University of Chicago

Enrollment

5 participants

Start Date

Jul 6, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The main purpose of this study is to determine whether differences in myocardial reserve predict clinical outcomes for heart failure patients.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study examines whether cardiac power output — a measurement taken during a right heart catheterization (a procedure where a thin tube is inserted into the heart's right side to measure blood flow and pressure) — can better predict outcomes in patients with severely weakened hearts who may need advanced treatments. **You may be eligible if...** - You are 18 or older with a reduced ejection fraction (heart pumping ability of 40% or less) - You are referred for right heart catheterization to evaluate whether you need advanced therapies like a heart pump, transplant, or IV heart medications - Your kidney function is adequate (eGFR ≥ 30 mL/min) **You may NOT be eligible if...** - You have very poor kidney function (eGFR below 30) - You have severe complications that make the procedure unsafe - You are not expected to be admitted to the hospital based on the catheterization results Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG1:1 Randomization to receive milrinone

Randomized to receive either inotropic agent: milrinone or no agent


Locations(1)

The University of Chicago

Chicago, Illinois, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05700617


Related Trials